All In Biotech

Drug Trial Radar · NCT01888497

Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, CROSS-OVER, PLACEBO-CONTROLLED, SINGLE DOSE, CLINICAL TRIAL TO ASSESS THE NEXT-DAY RESIDUAL EFFECTS OF GABAPENTIN, DIPHENHYDRAMINE AND TRIAZOLAM ON SIMULATED DRIVING PERFORMANCE IN NORMAL VOLUNTEERS

Last checked: Nov 20, 2026Latest source record: Feb 21, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

59

Actual

Start

Jul 29, 2013

Primary completion

Dec 14, 2013

Study completion Dec 14, 2013

Sponsor

Sponsor type
Industry
First posted
Jun 27, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 25 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will examine the next-day residual effects of a nighttime dose of gabapentin 250 mg, diphenhydramine citrate 76 mg and triazolam 0.5 mg compared to placebo and each other on simulated driving performance in normal volunteer subjects. It will also examine other measures of next-day performance and next-day sleepiness.

Conditions

  • Healthy

Interventions

  • GabapentinDrug

    250 mg, oral, prior to bedtime on the night before performance testing

  • Diphenhydramine citrateDrug

    76 mg, oral, prior to bedtime on the night before performance testing

  • TriazolamDrug

    0.5 mg, oral, prior to bedtime on the night before performance testing

  • PlaceboDrug

    Oral, prior to bedtime on the night before performance testing

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Standard Deviation of Lateral Position (SDLP)Time frame: 7.25 hours post-dose

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Baptist Sleep Centers, LLP

    South Miami, Florida

  • Miami Research Associates

    South Miami, Florida

  • NeuroTrials Research Sleep Lab

    Atlanta, Georgia

  • NeuroTrials Research, Inc.

    Atlanta, Georgia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.